Quarterly and annual results disclosed under 8-K Item 2.02.
Monopar Therapeutics reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share.
“Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share”
Monopar Therapeutics reported fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share.
“the fourth quarter and full-year 2025 financial results”
HYDROFARM HOLDINGS GROUP, INC. reported the fourth quarter and fiscal year ended December 31, 2025 results: revenue $25.1 million, net income $242.2 million, EPS $(51.89) per diluted share.
“Net sales in the fourth quarter of 2025 decreased 32.7% to $25.1 million compared to $37.3 million in the prior year period. This was primarily due to a 27.3% decline in volume/mix of products sold primarily related to industry oversupply, and a 5.6% decrease in price. Gross Profit increased to $2.1 million, or 8.5% of net sales, compared to $1.8 million, or 4.9% of net sales, in the prior year period. Adjusted Gross Profit (1) increased to $3.9 million, or 15.4% of net sales, compared to $3.6 million, or 9.6% of net sales, in the prior year period. Gross Profit, Adjusted Gross Profit (1) , Gross Profit Margin, and Adjusted Gross Profit Margin (1) improved as a result of higher sales of proprietary brands and improved productivity. These increases more than offset the impact of lower net sales. Selling, general and administrative (“SG&A”) expense was $9.6 million, compared to $17.0 million in the prior year period, and Adjusted SG&A (1) expense was $8.8 million compared to $10.8 millio”
BioXcel Therapeutics, Inc. reported financial results for for the three months and year ended December 31, 2025.
“On March 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update.”
Autolus Therapeutics plc reported the quarter and full year ended December 31, 2025 results: revenue $23.3 million. Guidance reaffirmed.
“Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates March 27, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025”
Werewolf Therapeutics, Inc. reported full year ended December 31, 2025 results: net income Net loss was $60.8 million.
“Net loss was $60.8 million for the full year 2025”
Werewolf Therapeutics, Inc. reported quarter ended December 31, 2025 results: net income Net loss was $8.4 million.
“Net loss was $8.4 million for the fourth quarter of 2025”
Instil Bio, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,, EPS Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,.
“On March 27, 2026, Instil Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025”
TMC the metals Co Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
“TMC Announces Fourth Quarter and Full Year 2025 Results”
Origin Materials, Inc. reported financial results for the year ended December 31, 2025.
“On March 27, 2026, Origin Materials, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
Forian Inc. reported financial results for quarter and year ended December 31, 2025.
“On March 27, 2026, the Company issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.”
Envoy Medical, Inc. reported full year ended December 31, 2025 results: revenue $241.
“Net Revenue was $241 as of December 31, 2025 compared to $225 for year ended December 31, 2024.”
Verde Clean Fuels, Inc. reported the year ended 2025 results: net income net loss of $(14.1) million, EPS diluted loss per share of Class A common stock of $(0.39).
“For the year ended 2025, the Company recorded a net loss of $(14.1) million and diluted loss per share of Class A common stock of $(0.39).”
Verde Clean Fuels, Inc. reported the fourth quarter 2025 results: net income net loss of $(6.6) million, EPS diluted net loss per share of Class A common stock of $(0.17).
“For the fourth quarter 2025, the Company recorded a net loss of $(6.6) million and diluted net loss per share of Class A common stock of $(0.17).”
Senti Biosciences, Inc. reported the year ended December 31, 2025 results: net income Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share, EPS $2.73 per share.
“Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results”
Calidi Biotherapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $25.6 million, or $5.95 per share, for the year ended December 31, 2025, EPS $5.95 per share.
“The company reported a net loss attributable to common stockholders of $4.1 million, or $0.57 per share, for the three months ended December 31, 2025”
SBC Medical Group Holdings Inc reported fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve mont results: revenue Total revenues were $40 million, net income Net Income attributable to SBC Medical Group was $14 million, EPS earnings per share ... was $0.14.
“year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025) Fourth Quarter 2025 Highlights ● Total revenues were $40 million, representing an 11% year-over-year decrease. ● Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. ● Earnings per share”
Legence Corp. reported the quarter and year ended December 31, 2025 results: revenue Revenues for the fourth quarter 2025 totaled $737.6 million. Guidance raised.
“On March 27, 2026, Legence Corp. (the “Company”) issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2025.”
ECOLAB INC. reported the years ended December 31, 2025 and December 31, 2024 results: revenue $16,081.2.
“16,298.4 15,273.4 - 725.4 15,998.8 Effect of foreign currency translation 514.0 - (731.2) (217.2) 468.0 - (725.4) (257.4) Total reported GAAP net sales $16,081.2 $ - $ - $16,081.2 $15,741.4 $ - $ - $15,741.4 Cost of Sales Global Water $4,585.9 ($2.3) ”
KOPIN CORP reported fourth quarter ended December 27, 2025 results: revenue $8.4 million.
“order flow normalize which we are experiencing now,” concluded Murray. Fourth Quarter 2025 Financial Results Total revenues for the fourth quarter ended December 27, 2025, were $8.4 million, as compared to $14.6 million for the fourth quarter ended December 28, 2024. The year-over-year decrease in revenues was primarily attributable to the government shutdown and”
STRATUS PROPERTIES INC reported year ended December 31, 2025 results: revenue $29.9 million, net income $12.0 million, or $1.47 per diluted share, EPS $1.47 per diluted share.
“2025, compared to net income attributable to common stockholders of $2.0 million, or $0.24 per diluted share, in the year ended December 31, 2024. • Revenues for 2025 totaled $29.9 million compared to revenues of $54.2 million for 2024. The decrease was primarily a result of sales in 2024 of five Amarra Villas homes for a total of $18.9 million, 47 acres of”
Enveric Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2025.”
INNOVATE Corp. reported the fourth quarter and full year ended December 31, 2025 results: revenue $ 382.7, net income $ (7.8), EPS $(0.58).
“Summary (in millions, except per share amounts) Three Months Ended December 31, Year Ended December 31, 2025 2024 Increase / (Decrease) 2025 2024 Increase / (Decrease) Revenue $ 382.7 $ 236.6 61.7 % $ 1,246.0 $ 1,107.1 12.5 % Net loss attributable to common stockholders and participating preferred stockholders $ (7.8) $ (16.9) 53.8 % $ (64.0) $ (35.8) (78.8) %”
ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2025 results: revenue $69.3 million, net income $ (5.3) million, EPS $ (0.15) per share.
“--- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth quarter 2025,”
ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2025 results: revenue $18.3 million, net income $ (0.6) million, EPS $ (0.01) per share.
“EX-99.1 (EX-99.1) --- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth”
VirTra, Inc reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 26, 2026, VirTra, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”
Designer Brands Inc. reported financial results for the three months and year ended January 31, 2026.
“the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. On March 26, 2026 , Designer Brands Inc. (the "Company") issued a press release announcing its consolidated financial results for the quarter and fiscal year ended January 31, 2026. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.”
22nd Century Group, Inc. reported the quarter and full year ended December 31, 2025 results: revenue $3.5 million, net income Net loss was $2.8 million.
“excluding discontinued operations related to the sale and exit of the Company’s hemp/cannabis business in late 2023, except as noted. ● Net revenues decreased slightly to $3.5 million from $4.0 million. ● Gross profit (loss) improved to $(0.8) million, compared to $(1.1) million. ● Operating expenses were $2.0 million, decreased from $2.2 million. ●”
CapsoVision, Inc reported the full year ended December 31, 2025 results: revenue $13.6 million.
“Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.”
CapsoVision, Inc reported the fourth quarter ended December 31, 2025 results: revenue $3.9 million.
“Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024.”
Dare Bioscience, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025, a copy of which is furnished as Exhibit 99.1 to this report.”
SANUWAVE Health, Inc. reported the fourth quarter and fiscal year ended December 31, 2025 results: revenue $13.4 million, net income $7.7 million. Guidance initiated.
“forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025 Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an”
Blink Charging Co. reported fourth quarter and full year ended December 31, 2025 results: revenue Total revenues were $27.0 million in the fourth quarter of 2025 and $103.5 million for full year 2025.. Guidance initiated.
“complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ CURRENT REPORT ON FORM 8-K Blink Charging Co. March 26, 2026 Item 2.02. Results of Operations and Financial Condition. Blink Charging Co. (Nasdaq: BLNK) (the “Company”), a leading owner and operator of electric vehicle (EV) charging”
COGNITION THERAPEUTICS INC reported the year ended December 31, 2025 results: net income $23.5 million, or $(0.32) per basic and diluted share, EPS $(0.32) per basic and diluted share.
“$12.3 million for 2024. The change in general and administrative expenses was driven primarily by reduced stock-based compensation expenses. The Company reported a net loss of $23.5 million, or $(0.32) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34.0 million, or $(0.86) per basic and diluted share for 2024. Conference”
Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.”
CV Sciences, Inc. reported the year and quarter ended December 31, 2025 results: revenue $13.8 million.
“its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights • Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for”
Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2025 results: net income Net loss was $121.3 million.
“Net loss was $121.3 million for the year ended Dec. 31, 2025, compared to $102.3 million for the year ended Dec. 31, 2024.”
Vroom, Inc. reported financial results for the quarter and year ended December 31, 2025.
“On March 26, 2026, Vroom, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”
SKYX Platforms Corp. reported fiscal year ended December 31, 2025 results: revenue $92.0 million.
“SKYX reports record sales $92.0 million in 2025 compared with $86 million in 2024.”
SKYX Platforms Corp. reported Q4 2025 results: revenue $25 million.
“Generated a record $25 million in revenue in Q-4 2025 compared to $24 million in Q-4 2024.”
DBV Technologies S.A. reported the fiscal year ended December 31, 2025 results: net income $147.0 million, EPS $1.05.
“Net loss was $147.0 million for the year ended December 31, 2025, compared to $113.9 million for the year ended December 31, 2024. Net loss per share (based on the weighted average number of shares outstanding over the period) was $1.05 and $1.17 for the year ended December 31, 2025 and 2024, respectively.”
Veritone, Inc. reported FY 2026 results: revenue $130 million - $145 million, net income $22.5 million - $13.5 million. Guidance initiated.
“FY 2026 outlook of Revenue of $130 million - $145 million and Non-GAAP Net Loss of $22.5 million - $13.5 million”
Veritone, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $18.1 million - $30.0 million, net income $37.0 million - $25.1 million.
“Q4 preliminary Revenue in the range of $18.1 million - $30.0 million* - – Q4 preliminary, unaudited GAAP net loss from continuing operations of $37.0 million - $25.1 million;”
LeonaBio, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2025, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025.”
MetaVia Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2025 and providing a corporate update.”
Laird Superfood, Inc. reported the fourth quarter and fiscal year ended December 31, 2025 results: revenue $49.9 million.
“99.1) --- EX-99.1 2 ex_892836.htm EXHIBIT 99.1 ex_892836.htm Exhibit 99.1 Laird Superfood Reports Fourth Quarter and Fiscal Year 2025 Financial Results Record Net Sales of $49.9 million for Fiscal Year 2025, growth of 15% year-over-year. Boulder, Colorado – March 26, 2026 – Laird Superfood, Inc. (NYSE American: LSF) (“Laird Superfood,” the “Company”, “we”, and”
Alpha Cognition Inc. reported the year ended December 31, 2025 results: revenue $10.2 million, net income $20.7 million.
“Full Year Fiscal 2025 Financial Results ● Revenues: ZUNVEYL net product revenues were $6.8 million, and licensing revenue totaled $3.4 million, for a combined total of $10.2 million for the year ended December 31, 2025. ● Research & Development: Expenses were $1.9 million, compared to $3.9 million for fiscal year 2024 as the Company transitioned to commercial stage. ● Selling, General & Administrative : Expenses were $29.1 million, up from $8.0 million in 2024, reflecting increased commercial investment in personnel and infrastructure. ● Operating Loss: $22.7 million, compared to $12.0 million in 2024. ● Net Loss: $20.7 million, compared to $14.8 million in 2024.”
Alpha Cognition Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.
“Net ZUNVEYL Revenue: Generated approximately $2.5 million in net product revenue in the fourth quarter of 2025.”
Quoin Pharmaceuticals, Ltd. reported financial results for fourth quarter and fiscal year 2025.
“Quoin Pharmaceuticals Ltd. (the "Company") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.”
Aptevo Therapeutics Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2025.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.